Submit a manuscript Sign up for article alerts Contact us Support

About Translational Neurodegeneration

This page includes information about the aims and scope of Translational Neurodegeneration, editorial policies, open access and article-processing charges, the peer review process and other information. For details of how to prepare and submit a manuscript through the online submission system, please see the instructions for authors.

Aims & scope

Translational Neurodegeneration is an open access, peer-reviewed journal that covers research, therapeutics and education for all aspects of neurodegenerative diseases. By offering a high-visibility forum for new insights and discussions, Translational Neurodegeneration creates a novel interface between the fields of basic, translational, and clinical research. It includes Parkinson's disease and movement disorders, Alzheimer's disease and other dementias, motor neuron disease and other neurodegenerative diseases.

Topics of interest include but are not limited to the following areas of neurodegenerative diseases:

  • Epidemiology and pathogenesis
  • Research into diagnosis and prevention
  • Research into the diease pathogenesis
  • Development of new drugs and cell therapy
  • Drug delivery
  • Rehabilitation

Translational Neurodegeneration offers the opportunity for basis scientists, clinicians and physician-scientists to publish their research and clinical trials in a journal which is applicable to their specific field.

Open access

All articles published by Translational Neurodegeneration are made freely and permanently accessible online immediately upon publication, without subscription charges or registration barriers. Further information about open access can be found here.

Authors of articles published in Translational Neurodegeneration are the copyright holders of their articles and have granted to any third party, in advance and in perpetuity, the right to use, reproduce or disseminate the article, according to the BioMed Central copyright and license agreement.

For authors who are US government employees or are prevented from being copyright holders for similar reasons, BioMed Central can accommodate non-standard copyright lines. Please contact us if further information is needed.

Article-processing charges

Open access publishing is not without costs. Translational Neurodegeneration therefore levies an article-processing charge of £1240/$1940/€1580 for each article accepted for publication. If the corresponding author's institution is a Member, the cost of the article-processing charge is covered by the membership, and no further charge is payable. In the case of authors whose institutions are Supporter Members, however, a discounted article-processing charge is payable by the author. We routinely waive charges for authors from low-income countries. For other countries, article-processing charge waivers or discounts are granted on a case-by-case basis to authors with insufficient funds. Authors can request a waiver or discount during the submission process. For further details, see our article-processing charge page.

Indexing services

All articles published in Translational Neurodegeneration are included in:

  • CAS
  • DOAJ
  • PubMed
  • PubMed Central
  • Scopus

The full text of all research articles is deposited in digital archives including e-Depot (The Netherlands).

The full text of all research articles published by BioMed Central is also available on SpringerLink.

BioMed Central is working closely with Thomson Reuters (ISI) to ensure that citation analysis of articles published in Translational Neurodegeneration will be available.

Publication and peer review process

Content overview

Translational Neurodegeneration considers the following types of articles:

  • Research:reports of data from original research.
  • Reviews: of any topic within the scope of the journal. They may be either invited by the editor or unsolicited. Plenary lectures from Conferences and specialized meetings are welcomed. These may include the slides and videos that were used in the original presentation. Authors and conference organizers are encouraged to discuss proposals with the Editor at an early stage. All reviews will be peer-reviewed.
  • Case reports: reports of clinical cases that can be educational, describe a diagnostic or therapeutic dilemma, suggest an association, or present an important adverse reaction. Reports may suggest the need for a change in practice or thinking in terms of diagnosis or prognosis, but not in terms of preventative or therapeutic intervention, which require stronger evidence.
  • Short reports: brief reports of data from original research, usually about 1500 words.
  • Discussion of articles published in the journal is encouraged, and these contributions will be included in Readers' Comments, accessed from the web page on which the article is displayed. These comments are subject to editing and remain in the Archives associated with the specific article to which they refer.

Peer-review policies

Manuscripts will be reviewed by internationally recognized experts in the field, selected in part from the Editorial Board. Reviews will be rapid and the suitability of a manuscript for publication will be assessed solely on criteria of scientific excellence. Final decisions will be made by the Editor-in-Chief and may include accept, reject, accept following minor revision and resubmit after major revision and further review.

Edited by Shengdi Chen, Translational Neurodegeneration is supported by an expert Editorial Board.

Authors will be able to check the progress of their manuscript through the submission system at any time by logging into My Translational Neurodegeneration, a personalized section of the site.


High-quality, bound reprints can be purchased for all articles published. Please see our reprints website for further information about ordering reprints.


Translational Neurodegeneration will consider supplements based on proceedings (full articles or meeting abstracts), reviews or research. All articles submitted for publication in supplements are subject to peer review. Published supplements are fully searchable and freely accessible online and can also be produced in print. For further information, please contact us.

Editorial policies

All manuscripts submitted to Translational Neurodegeneration should adhere to BioMed Central's editorial policies.

Citing articles in Translational Neurodegeneration

Articles in Translational Neurodegeneration should be cited in the same way as articles in a traditional journal. Because articles are not printed, they do not have page numbers; instead, they are given a unique article number.

Article citations follow this format:

Authors: Title. Transl Neurodegener [year], [volume number]:[article number].

e.g. Roberts LD, Hassall DG, Winegar DA, Haselden JN, Nicholls AW, Griffin JL: Increased hepatic oxidative metabolism distinguishes the action of Peroxisome Proliferator-Activated Receptor delta from Peroxisome Proliferator-Activated Receptor gamma in the Ob/Ob mouse. Transl Neurodegener 2009, 1:115.

refers to article 115 from Volume 1 of the journal.

Why publish your article in Translational Neurodegeneration?

High visibility

Translational Neurodegeneration's open access policy allows maximum visibility of articles published in the journal as they are available to a wide, global audience. Articles that have been especially highly accessed are highlighted with a 'Highly accessed' graphic, which appears on the journal's contents pages and search results.

Speed of publication

Translational Neurodegeneration offers a fast publication schedule whilst maintaining rigorous peer review; all articles must be submitted online, and peer review is managed fully electronically (articles are distributed in PDF form, which is automatically generated from the submitted files). Articles will be published with their final citation after acceptance, in both fully browsable web form, and as a formatted PDF; the article will then be available through Translational Neurodegeneration and BioMed Central.


Online publication in Translational Neurodegeneration gives authors the opportunity to publish large datasets, large numbers of color illustrations and moving pictures, to display data in a form that can be read directly by other software packages so as to allow readers to manipulate the data for themselves, and to create all relevant links (for example, to PubMed, to sequence and other databases, and to other articles).

Promotion and press coverage

Articles published in Translational Neurodegeneration are included in article alerts and regular email updates. Some may be included in abstract books mailed to academics and are highlighted on Translational Neurodegeneration's pages and on the BioMed Central homepage.

In addition, articles published in Translational Neurodegeneration may be promoted by press releases to the general or scientific press. These activities increase the exposure and number of accesses for articles published in Translational Neurodegeneration. A list of articles recently press-released by journals published by BioMed Central is available here.

Authors of articles published in Translational Neurodegeneration retain the copyright of their articles and are free to reproduce and disseminate their work (for further details, see the BioMed Central copyright policy and license agreement).

For further information about the advantages of publishing in a journal from BioMed Central, please click here.